Filing Flows › Century Therapeutics (IPSC) › Q1 2025
Century Therapeutics (IPSC) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Century Therapeutics (IPSC) reported revenue of $109M for the first quarter 2025 (Q1 2025), up 128-fold from a year earlier and up 26-fold from the quarter before. Operating margin was 67.9%, net earnings $76.6M (70.1% of revenue).
Century Therapeutics, Q1 2025: revenue $109M (128× year over year), operating margin 67.9%, net earnings $76.6M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $109M | 26× | 128× |
| Operating profit | $74.2M | — | — |
| Net earnings | $76.6M | — | — |
| Operating cash flow | −$34.6M | — | — |
What changed
Revenue was $109.2M in Q1 2025, up 12668% year over year and up 2516% from the previous quarter.
Operating profit was $74.2M, a 67.9% margin (up 3729.8 points year over year). Total costs grew 9% against revenue growth of 12668%. The fastest-growing cost line was Research & development (+13%). Net earnings were $76.6M. The effective tax rate was 0.0%.
Operating cash flow was −$34.6M. Non-cash charges added back $3.2M of depreciation and $2.4M of share-based compensation. Working capital and other items used $116.8M. Capital expenditures of $475K exceeded it, leaving free cash flow of −$35.1M.
Questions
What was Century Therapeutics' revenue in the first quarter 2025?
Century Therapeutics (IPSC) reported revenue of $109M for the first quarter 2025 (Q1 2025), up 128-fold from a year earlier and up 26-fold from the quarter before.
Was Century Therapeutics profitable in the first quarter 2025?
Operating profit was $74.2M (67.9% of revenue) and net earnings $76.6M.